Collegium Pharmaceutical, Inc. Profile Avatar - Palmy Investing

Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta …

Drug Manufacturers - Specialty & Generic
US, Stoughton [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Collegium Pharmaceutical, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of COLL's Analysis
CIK: 1267565 CUSIP: 19459J104 ISIN: US19459J1043 LEI: - UEI: -
Secondary Listings
COLL has no secondary listings inside our databases.